Flying to Istanbul for stem cell therapy? Learn exactly what happens at your first consultation — assessments, protocols, and honest outcome expectations.
Most people who contact us aren't looking for a shortcut. They've been through years of conventional treatment — medications adjusted and readjusted, physiotherapy, specialist after specialist. Some are managing a progressive neurological condition. Others are living with joint pain that limits every day. A few are supporting a family member who has stopped improving with standard care.
Mesenchymal stem cells are a class of adult stem cells found in several tissues — bone marrow, adipose tissue, and umbilical cord tissue, among others. They don't work the way many people imagine. They don't travel to damaged tissue and directly replace lost cells. What they primarily do is communicate.
MSC therapy has over 15 years of clinical investigation behind it. The first significant human trials go back to the early 2000s, initially in graft-versus-host disease following bone marrow transplantation. Since then, thousands of patients have been enrolled in registered clinical trials covering conditions including multiple sclerosis, Crohn's disease, rheumatoid arthritis, heart failure, stroke recovery, COPD, and type 2 diabetes. This is a well-established research platform.
Exosome therapy as a standalone clinical treatment has a shorter track record than MSC therapy. The underlying science of extracellular vesicles is well-established — we understand the biology. But dedicated human trials for exosome-only protocols are earlier-stage, with most registered studies beginning post-2015. The signals are promising. The evidence base is still being built.
Candidacy is determined case by case. There is no universal patient profile. But certain patterns do appear consistently across the conditions we treat.
The consultation is the foundation of everything. It runs 60 to 90 minutes and covers every relevant clinical dimension of your case.
We use mesenchymal stem cells derived from ethically donated umbilical cord tissue — specifically Wharton's jelly, the gelatinous substance within the cord. These cells are collected at birth, from consenting donors, under rigorous ethical protocols. They're young cells with high proliferative capacity, and they carry no donor-recipient matching requirement for allogeneic use.
Most patients don't notice changes in the days immediately following treatment. The paracrine and immunomodulatory mechanisms MSCs activate take time to produce observable effects. Most patients who respond to therapy begin noticing changes over three to six months — sometimes subtly at first. Reduced fatigue. Slightly improved mobility. A lower frequency of flares in an autoimmune condition.
The short-to-medium-term safety profile of umbilical cord MSCs administered intravenously is well-documented across the clinical trial literature. Common, transient side effects include mild fever, fatigue, or flu-like symptoms in the 24–48 hours following infusion — consistent with a mild immune response to the new cellular material. These resolve without intervention in the large majority of cases.
The majority of our international patients travel from the United Kingdom, United States, Australia, and the Gulf region. A typical visit involves a stay of three to seven days in Istanbul — enough time for the initial consultation, any necessary additional assessments, the treatment session itself (which runs one to two hours as an outpatient procedure), and a brief recovery period before departure.
Safety depends on which cells are used, how they're prepared, what route of administration is chosen, and whether the patient's clinical profile is appropriate. Umbilical cord MSCs have a well-documented safety record across thousands of patients in clinical trials spanning more than 15 years. At a regulated clinic with GMP-aligned processing and proper patient screening, the risk profile is very different from unregulated offerings promising guaranteed outcomes. We discuss individual risk factors with every patient before any decision is made.
Not automatically. Many patients continue their standard medications throughout treatment. But some drugs — particularly high-dose immunosuppressants or certain biologics — may interact with cell activity and require adjustment. This is reviewed carefully during your consultation. Never stop or adjust prescribed medications without guidance from your treating physician.
Meaningful clinical signals typically emerge over three to six months. Some patients notice earlier changes; others see the clearest results in the six-month assessment. We monitor you at structured intervals and use objective measures — not just reported symptoms — to evaluate response. If there's no meaningful benefit by six months, we'll say so honestly and discuss what comes next.
Our clinical programme covers neurological conditions (including multiple sclerosis and stroke recovery), autoimmune disorders, rheumatoid arthritis, osteoarthritis, liver disease, cardiovascular disease, COPD, kidney disease, type 2 diabetes, and aesthetic exosome protocols. Each indication has a different evidence base, and we're transparent about where the research is stronger and where it's still evolving. Candidacy is assessed individually — the same diagnosis doesn't produce the same protocol for every patient.
No. Stem cell therapy at our clinic is always complementary to conventional medical care — not a replacement for it. If you're on disease-modifying therapy for MS, we're not asking you to stop. If you're managing rheumatoid arthritis with a rheumatologist, that relationship continues. We work alongside your existing care team, and we'll write to your home-country physicians with a full clinical summary.
Costs vary based on the protocol — cell dose, number of sessions, and administration route all affect the total. International patients typically find that high-quality regulated stem cell therapy in Istanbul is substantially more accessible than equivalent-standard offerings in the UK, US, or Australia, where regulatory pathways are more restrictive and private-pay costs are significantly higher. Your coordinator will provide a full transparent cost breakdown after the clinical assessment, with no hidden fees.
We tell you. And we try to explain why, clearly, so you can make informed decisions about your next steps. In some cases we'll suggest a different intervention entirely, or recommend you revisit the question after a change in your condition. Turning patients away when it's the right clinical answer isn't a failure — it's the only honest thing to do.
Stem cell therapy sits at an interesting point in medicine right now. It's not experimental in any meaningful sense — not with 15-plus years of clinical trial data and thousands of enrolled patients behind it. But it's also not a finished science. The best clinics operate in that space honestly: applying what's well-evidenced, being transparent about what isn't, and treating every patient as a person with a real condition and reasonable questions.
Stem Cell Therapy in Istanbul: What to Expect From Your First Consultation